|
1
|
Lavanchy D: The global burden of hepatitis
C. Liver Int. 29(Suppl 1): 74–81. 2009. View Article : Google Scholar
|
|
2
|
Bota S, Sporea I, Popescu A, Sirli R,
Neghina AM, Danila M and Strain M: Response to standard of care
antiviral treatment in patients with HCV liver cirrhosis - a
systematic review. J Gastrointestin Liver Dis. 20:293–298.
2011.PubMed/NCBI
|
|
3
|
Michielsen P, Ho E and Francque S: Does
antiviral therapy reduce the risk of hepatocellular carcinoma in
patients with chronic hepatitis C? Minerva Gastroenterol Dietol.
58:65–79. 2012.PubMed/NCBI
|
|
4
|
Ghany MG, Strader DB, Thomas DL and Seeff
LB: American Association for the Study of Liver Diseases:
Diagnosis, management, and treatment of hepatitis C: an update.
Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Asian Pacific Association for the Study of
the Liver (APASL) Hepatitis C Working Party. McCaughan GW, Omata M,
Amarapurkar D, et al: Asian Pacific Association for the Study of
the Liver consensus statements on the diagnosis, management and
treatment of hepatitis C virus infection. J Gastroenterol Hepatol.
22:615–633. 2007. View Article : Google Scholar
|
|
6
|
Guedj H, Guedj J, Negro F, et al: The
impact of fibrosis and steatosis on early viral kinetics in HCV
genotype 1-infected patients treated with Peg-IFN-alfa-2a and
ribavirin. J Viral Hepat. 19:488–496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heathcote EJ, Shiffman ML, Cooksley WG, et
al: Peginterferon alfa-2a in patients with chronic hepatitis C and
cirrhosis. N Engl J Med. 343:1673–1680. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gordon SC: Treatment of viral
hepatitis-2001. Ann Med. 33:385–390. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu JW and Wang W: The relationship of rat
fibrosis and hyaluronic acid and related proteins. Chinese Journal
of Anatomy. 23:2682010.(In Chinese).
|
|
10
|
Cui AL: Treatment of 54 cases of active
hepatocirrhosis with lamivudine combined with Fu Zheng Hua Yu
capsule. Journal of China Pharmaceutical. 21:74–75. 2012.(In
Chinese).
|
|
11
|
De Bleser PJ, Niki T, Xu G, Rogiers V and
Geerts A: Localization and cellular sources of activins in normal
and fibrotic rat liver. Hepatology. 26:905–912. 1997.PubMed/NCBI
|
|
12
|
Brenndörfer ED, Weiland M, Frelin L, et
al: Anti-tumor necrosis factor α treatment promotes apoptosis and
prevents liver regeneration in a transgenic mouse model of chronic
hepatitis C. Hepatology. 52:1553–1563. 2010.
|
|
13
|
Tan CY, Tan SZ, Jiang J and Xu LM: Effects
of ‘Fuzheng Huayu Decoction’ on hepatocellular apoptosis in rats
with DMN liver fibrosis. Shanghai Journal of Traditional Chinese
Medicine. 39:47–49. 2005.(In Chinese).
|
|
14
|
Prati GM, Aghemo A, Rumi MG, et al:
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with
hepatitis C-related advanced fibrosis. J Hepatol. 56:341–347.
2012.PubMed/NCBI
|
|
15
|
Bzowej N, Nelson DR, Terrault NA, et al:
PHOENIX: A randomized controlled trial of peginterferon alfa-2a
plus ribavirin as a prophylactic treatment after liver
transplantation for hepatitis C virus. Liver Transpl. 17:528–538.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park CH, Kim DH, Park MH, et al: Chinese
prescription Kangen-karyu and Salviae Miltiorrhizae radix
improve age-related oxidative stress and inflammatory response
through the PI3K/Akt or MAPK pathways. Am J Chin Med. 42:987–1005.
2014.
|
|
17
|
Teng H and Lee WY: Antibacterial and
antioxidant activities and chemical compositions of volatile oils
extracted from Schisandra chinensis Baill. seeds using
simultaneous distillation extraction method, and comparison with
Soxhlet and microwave-assisted extraction. Biosci Biotechnol
Biochem. 78:79–85. 2014.PubMed/NCBI
|
|
18
|
Yu HY, Chen ZY, Sun B, et al: Lignans from
the fruit of Schisandra glaucescens with antioxidant and
neuroprotective properties. J Nat Prod. 77:1311–1320. 2014.
|
|
19
|
Cheng N, Ren N, Gao H, Lei X, Zheng J and
Cao W: Antioxidant and hepatoprotective effects of Schisandra
chinensis pollen extract on CCl4-induced acute liver damage in
mice. Food Chem Toxicol. 55:234–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li TF, Qin MZ and Hu SS: The expression of
Fas and FasL in PBMC of multiple sclerosis patients. Shanghai
Journal of Immunology. 22:1312002.(In Chinese).
|
|
21
|
Alkahtani S: Hepatitis C infection and
apoptosis in hepatocellular carcinoma. Pak J Biol Sci. 12:804–808.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zaki Mel S, Auf FA, Ghawalby NA and Saddal
NM: Clinical significance of serum soluble Fas, Fas ligand and fas
in intrahepatic lymphocytes in chronic hepatitis C. Immunol Invest.
37:163–170. 2008.PubMed/NCBI
|
